Travere Therapeutics's market cap is currently $2.20B. The company's EPS TTM is $-0.14; its P/E ratio is ―; Travere Therapeutics is scheduled to report earnings on August 6, 2025, and the estimated EPS forecast is $-0.30. See an overview of income statement, balance sheet, and cash flow financials.
